- Poland
- /
- Medical Equipment
- /
- WSE:CRM
PZ Cormay First Quarter 2025 Earnings: EPS: zł0.007 (vs zł0.003 loss in 1Q 2024)
PZ Cormay (WSE:CRM) First Quarter 2025 Results
Key Financial Results
- Revenue: zł22.8m (up 1.8% from 1Q 2024).
- Net income: zł580.0k (up from zł279.0k loss in 1Q 2024).
- Profit margin: 2.5% (up from net loss in 1Q 2024).
- EPS: zł0.007 (up from zł0.003 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PZ Cormay shares are up 4.7% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for PZ Cormay you should be aware of, and 1 of them is potentially serious.
If you're looking to trade PZ Cormay, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:CRM
PZ Cormay
Develops, manufactures, and sells diagnostic reagents in Poland.
Adequate balance sheet and slightly overvalued.
Market Insights
Community Narratives

